Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ireland TYSABRI (Natalizumab) Observational Program (iTOP)

Trial Profile

Ireland TYSABRI (Natalizumab) Observational Program (iTOP)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms iTOP
  • Sponsors Biogen
  • Most Recent Events

    • 15 Oct 2021 Results (As of December 2017) presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 03 May 2018 Status changed from active, no longer recruiting to completed.
    • 10 Jul 2015 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top